Discovery and Characterization of Novel IKZF1/3 Glue Degraders against Multiple Hematological Cancer Cell Lines
These results indicate that MGD-C9 could act as a highly effective CRBN ligand and is expected to become a candidate drug for the treatment of hematological malignancies.
Authors
- Shiyang Sun
- Min Qiao
- Changkai Jia
- Hongzhou Shang
- Yifeng Zou (ORCID: https://orcid.org/0000-0002-0226-6924)
- Pengyun Li (ORCID: https://orcid.org/0000-0003-1592-6554)
- Pengli Wei
- Ting Wei
- Zhibing Zheng (ORCID: https://orcid.org/0000-0002-0278-2531)
- Cai Xu (ORCID: https://orcid.org/0000-0002-1412-4229)
- Tingting Yang (ORCID: https://orcid.org/0000-0002-5220-588X)
- Xiaotong Hu (ORCID: https://orcid.org/0000-0001-9068-743X)
- Zhiyuan Zhao (ORCID: https://orcid.org/0009-0001-6455-7452)
- Yalei Wang (ORCID: https://orcid.org/0000-0001-9072-9302)
- Bingkun Li (ORCID: https://orcid.org/0000-0001-6822-9440)
- Jian Yan (ORCID: https://orcid.org/0000-0003-0258-0697)
- Zhenze Qi (ORCID: https://orcid.org/0009-0001-6448-2219)
- Yaqiu Mao (ORCID: https://orcid.org/0009-0008-2913-2425)
Institutions
- North China University of Science and Technology (CN)
- Peking University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.065123
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00